Un nou article publicat a la revista The Lancet Respiratory Medicine pel Dr. Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Investigador ICREA i Professor de Gen\u00e8tica de la Universitat de Barcelona, mostra que un patr\u00f3 d’alteracions epigen\u00e8tiques en c\u00e0ncer de pulm\u00f3 permet predir si el tumor respondr\u00e0 a la ter\u00e0pia amb l’antic\u00f2s anti-PD-1, la immunoter\u00e0pia m\u00e9s freq\u00fcentment emprada en oncologia.<\/p>\n
\u00a0<\/p>\n
“De vegades, les c\u00e8l\u00b7lules tumorals aconsegueixen amagar-se de manera que el nostre sistema immune, habitualment molt efica\u00e7, no les reconeix, i per tant no les destrueix. La immunoter\u00e0pia actual aconsegueix treure aquest disfressa a la c\u00e8l\u00b7lula cancerosa perqu\u00e8 les nostres c\u00e8l\u00b7lules de defensa, com els limf\u00f2cits T i B, puguin actuar contra ella”, explica el Dr. Manel Esteller. No obstant aix\u00f2, hi han diversos tipus de tumors contra els quals la immunoter\u00e0pia \u00e9s inefica\u00e7. Fins i tot dins dels immunosensibles, com el c\u00e0ncer de pulm\u00f3, rony\u00f3, o el melanoma, nom\u00e9s un 30-40% responen efectivament a llarg termini. “Aix\u00ed doncs, \u00e9s important con\u00e8ixer pr\u00e8viament si un tumor ser\u00e0 o no sensible a la immunoter\u00e0pia, considerant a m\u00e9s que s\u00f3n f\u00e0rmacs cars i no exempts d’efectes secundaris”, afegeix l’investigador.<\/p>\n
\u00a0<\/p>\n
“Les marques epigen\u00e8tiques, com la metilaci\u00f3 de l’ADN, actuen com a interruptors capa\u00e7os d’encendre o apagar els nostres gens. Per aix\u00f2 pensem que tamb\u00e9 haurien de participar en els programes que la c\u00e8l\u00b7lula tumoral fa servir per escapar-se del control del sistema immune”, comenta el Dr. Esteller. Mitjan\u00e7ant l’estudi de centenars de tumors de pulm\u00f3, els investigadors de l’IDIBELL es van adonar que aquells que presentaven una empremta epigen\u00e8tica concreta, que han anomenat EPIMMUNE, responien molt b\u00e9 a la quimioter\u00e0pia en comparaci\u00f3 amb els que no la tenien. La signatura EPIMMUNE es troba en una tercera part dels c\u00e0ncers de pulm\u00f3 i s\u2019associa a enriquiment en limf\u00f2cits T i B.<\/p>\n
\u00a0<\/p>\n
Davant d’aquests resultats, l’equip vol seguir explorant aquesta l\u00ednia de recerca. “Ara volem estendre aquest tipus d’estudi a d\u2019altres tipus tumorals i a altres immunoter\u00e0pies, com ara emprant anticossos anti-PD-L1 o anti-CTCLA4. A m\u00e9s, aquest treball \u00e9s un exemple de la suma d’esfor\u00e7os d’investigadors b\u00e0sics, aplicats i cl\u00ednics, aix\u00ed com de la combinaci\u00f3 d’inversi\u00f3 p\u00fablica i de fundacions com l’Obra Social de La Caixa, sense la qual la recerca no hagu\u00e9s estat possible”, conclou el Dr. Esteller.
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"
Un nou article publicat a la revista The Lancet Respiratory Medicine pel Dr. Manel Esteller, director del Programa d’Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Investigador ICREA i Professor de Gen\u00e8tica de la Universitat de Barcelona, mostra que un patr\u00f3 d’alteracions epigen\u00e8tiques en c\u00e0ncer de pulm\u00f3 permet predir si […]<\/p>\n","protected":false},"author":6,"featured_media":10558,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,376],"tags":[],"class_list":["post-7601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-epigenetica-del-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 22:30:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7601"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7601\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10558"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}